Particulate Matter 2.5 Pollution Impact on Comorbid Cancer and Cardiovascular Disease Mortality in the U.S.

PM 2.5 exposure cancer cardio-oncology cardiovascular disease

Journal

JACC. Advances
ISSN: 2772-963X
Titre abrégé: JACC Adv
Pays: United States
ID NLM: 9918419284106676

Informations de publication

Date de publication:
Aug 2024
Historique:
received: 07 01 2024
revised: 08 06 2024
accepted: 09 06 2024
medline: 24 10 2024
pubmed: 24 10 2024
entrez: 24 10 2024
Statut: epublish

Résumé

Evidence regarding the effect of long-term exposure to particulate matter (PM) 2.5 and comorbid cancer and cardiovascular disease (CVD) mortality is limited. In this study, the author report the association between long-term exposure to PM 2.5 and CVD mortality, cancer mortality and comorbid cancer and CVD mortality in the U.S. population. The Centers for Disease Control and Prevention (CDC) WONDER (Wide-Ranging Online Data for Epidemiologic Research) multiple-cause-of-death database was used to obtain U.S. county-level mortality and population estimates from 2016 to 2020. Data on average daily density of PM 2.5 were abstracted from the 2018 CDC's National Environmental Public Health Tracking system. Counties were divided into quartiles with Q1 representing counties with least average daily density and Q4 representing counties with maximum average daily density of PM 2.5. Age-adjusted mortality rates were abstracted for each quartile, for the overall population and subgroups of population. The age-adjusted mortality rates for CVD, cancer, and comorbid cancer and CVD mortality were 505.3 (range: 505.0-505.7), 210.7 (range: 210.5-210.9), and 62.0 (range: 61.8-62.1) per 100,000 person-years, respectively. CVD mortality had the highest percentage excess mortality in Q4 compared with Q1, followed by comorbid cancer and CVD. Cancer had the least percentage excess mortality. A disproportionate effect of PM 2.5 exposure was noted on vulnerable and minority groups, based on Social Vulnerability Index and race stratification, respectively. Higher levels of long-term PM 2.5 exposure reported increased CVD mortality, cancer mortality and comorbid cancer and CVD disease mortality, with a pronounced detrimental effect in vulnerable and minority population.

Sections du résumé

Background UNASSIGNED
Evidence regarding the effect of long-term exposure to particulate matter (PM) 2.5 and comorbid cancer and cardiovascular disease (CVD) mortality is limited.
Objectives UNASSIGNED
In this study, the author report the association between long-term exposure to PM 2.5 and CVD mortality, cancer mortality and comorbid cancer and CVD mortality in the U.S. population.
Methods UNASSIGNED
The Centers for Disease Control and Prevention (CDC) WONDER (Wide-Ranging Online Data for Epidemiologic Research) multiple-cause-of-death database was used to obtain U.S. county-level mortality and population estimates from 2016 to 2020. Data on average daily density of PM 2.5 were abstracted from the 2018 CDC's National Environmental Public Health Tracking system. Counties were divided into quartiles with Q1 representing counties with least average daily density and Q4 representing counties with maximum average daily density of PM 2.5. Age-adjusted mortality rates were abstracted for each quartile, for the overall population and subgroups of population.
Results UNASSIGNED
The age-adjusted mortality rates for CVD, cancer, and comorbid cancer and CVD mortality were 505.3 (range: 505.0-505.7), 210.7 (range: 210.5-210.9), and 62.0 (range: 61.8-62.1) per 100,000 person-years, respectively. CVD mortality had the highest percentage excess mortality in Q4 compared with Q1, followed by comorbid cancer and CVD. Cancer had the least percentage excess mortality. A disproportionate effect of PM 2.5 exposure was noted on vulnerable and minority groups, based on Social Vulnerability Index and race stratification, respectively.
Conclusions UNASSIGNED
Higher levels of long-term PM 2.5 exposure reported increased CVD mortality, cancer mortality and comorbid cancer and CVD disease mortality, with a pronounced detrimental effect in vulnerable and minority population.

Identifiants

pubmed: 39444413
doi: 10.1016/j.jacadv.2024.101106
pii: S2772-963X(24)00300-4
pmc: PMC11496976
doi:

Types de publication

Journal Article

Langues

eng

Pagination

101106

Informations de copyright

© 2024 The Authors.

Déclaration de conflit d'intérêts

The authors have reported that they have no relationships relevant to the contents of this paper to disclose.

Auteurs

Ashish Kumar (A)

Department of Internal Medicine, Cleveland Clinic, Akron General, Akron, Ohio, USA.

Sumanth Khadke (S)

Division of Cardiovascular Medicine, Department of Cardiovascular Medicine, Lahey Hospital & Medical Center, Burlington, Massachusetts, USA.

Sadeer AlKindi (S)

Department of Cardiovascular Medicine, Houston Methodist Hospital, Houston, Texas, USA.

Sanjay Rajagopalan (S)

Division of Cardiovascular Medicine, Harrington Heart and Vascular Institute, University Hospitals and Case Western Reserve University, Cleveland, Ohio, USA.

Khurram Nasir (K)

Department of Cardiovascular Medicine, Houston Methodist Hospital, Houston, Texas, USA.

Dhruv Kazi (D)

Richard A. and Susan F. Smith Center for Outcomes Research, Division of Cardiology, Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA.

Javaria Ahmad (J)

Division of Cardiovascular Medicine, Department of Cardiovascular Medicine, Lahey Hospital & Medical Center, Burlington, Massachusetts, USA.

Safi Khan (S)

Department of Cardiovascular Medicine, Houston Methodist Hospital, Houston, Texas, USA.

Aarti Asnani (A)

Department of Cardiovascular Medicine, Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA.

Daniel Addison (D)

Department of Cardiovascular Medicine, Ohio State University; Columbus, Ohio, USA.

Diego Sadler (D)

Department of Cardiovascular Medicine, Cleveland Clinic Florida; Weston, Florida, USA.

Anita Deswal (A)

Department of Cardiovascular Medicine, University of Texas MD Anderson Cancer Center, Houston, Texas, USA.

Ana Barac (A)

Department of Cardiovascular Medicine, Inova Heart and Vascular Institute, Annandale, Virginia, USA.

Avirup Guha (A)

Department of Cardiovascular Medicine, Medical College of Georgia, Augusta, Georgia, USA.

Jennifer Liu (J)

Department of Cardiovascular Medicine, Memorial Sloan Kettering Cancer Center, New York City, New York, USA.

Daniel Lenihan (D)

Department of Cardiovascular Medicine, Washington University School of Medicine, St. Louis, Missouri, USA.

Tomas G Neilan (TG)

Department of Cardiovascular Medicine, Harvard Medical School, Boston, Massachusetts, USA.

Salim Hayek (S)

Department of Cardiovascular Medicine, University of Michigan, Ann Arbor, Michigan, USA.

Joerg Hermann (J)

Department of Cardiovascular Medicine, Mayo Clinic, Rochester, Minnesota, USA.

Anju Nohria (A)

Cardio-Oncology Program, Department of Cardiovascular Medicine, Brigham and Women's Hospital, Boston, Massachusetts, USA.

Sourbha S Dani (SS)

Division of Cardiovascular Medicine, Department of Cardiovascular Medicine, Lahey Hospital & Medical Center, Burlington, Massachusetts, USA.

Sarju Ganatra (S)

Division of Cardiovascular Medicine, Department of Cardiovascular Medicine, Lahey Hospital & Medical Center, Burlington, Massachusetts, USA.

Classifications MeSH